Priming with a recombinant pantothenate auxotroph of mycobacterium bovis bcg and boosting with mva elicits HIV-1 gag specific CD8 + T cells

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Chapman, Rosamund ^a   Shephard, Enid ^a,b,c   Stutz, Helen ^a   Douglass, Nicola ^a   Sambandamurthy, Vasan ^d   Garcia, Irene ^e   Ryffel, Bernhard ^f   Jacobs, William ^g   Williamson, Anna Lise ^a,h  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d ASTRAZENECA   (United Kingdom)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f CNRS   (France)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAG PROTEIN; KANAMYCIN; PANTOTHENIC ACID; VACCINIA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUXOTROPHY; BACTERIAL STRAIN; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CODON; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE FUSION; GENE SEQUENCE; GENETIC STABILITY; GROUP SPECIFIC ANTIGEN GENE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROMOTER REGION; SIGNAL TRANSDUCTION; VACCINIA VIRUS; VIRUS GENE; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE MUTANT; SPLEEN; VACCINATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

AIDS VACCINES; ANIMALS; BCG VACCINE; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV-1; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; MICE, SCID; MYCOBACTERIUM BOVIS; PANTOTHENIC ACID; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINIA VIRUS;

EID: 84859069751     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032769     Document Type: Article

References (61)

1. Honeyborne I, Prendergast A, Pereyra F, Leslie A, Crawford H, et al. (2007) Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8(+) T-cell epitopes. Journal of Virology 81: 3667-3672.
2. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8(+) T-cell responses to different HIV proteins have discordant associations with viral load. Nature Medicine 13: 46-53.
3. Letvin NL, (2002) Strategies for an HIV vaccine. J Clin Invest 110: 15-20.
4. Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, et al. (2006) Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity (vol 79, pg 12871, 2005). Journal of Virology 80: 10288.
5. Cayabyab MJ, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, et al. (2009) Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol 83: 5505-5513.
6. Chege GK, Thomas R, Shephard EG, Meyers A, Bourn W, et al. (2009) A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine 27: 4857-4866.
7. Aldovini A, Young RA, (1990) Development of a BCG recombinant vehicle for candidate AIDS vaccines. Int Rev Immunol 7: 79-83.
8. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, et al. (1991) New use of BCG for recombinant vaccines. Nature 351: 456-460.
9. Hanson MS, Bansal GP, Langermann S, Stover CK, Orme I, (1995) Efficacy and safety of live recombinant BCG vaccines. Dev Biol Stand 84: 229-236.
10. Dennehy M, Bourn W, Steele D, Williamson AL, (2007) Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine. Vaccine 25: 3646-3657.
11. Fennelly GJ, Flynn JL, ter Meulen V, Liebert UG, Bloom BR, (1995) Recombinant bacille Calmette-Guerin priming against measles. J Infect Dis 172: 698-705.
12. Govan VA, Williamson AL, (2007) Rabbits immunised with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L2E7E2 genes induces regression of established papillomas. Virus Research 127: 43-48.
13. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, et al. (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115: 2472-2479.
14. Langermann S, Palaszynski S, Sadziene A, Stover CK, Koenig S, (1994) Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 372: 552-555.
15. Stover CK, Bansal GP, Hanson MS, Burlein JE, Palaszynski SR, et al. (1993) Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med 178: 197-209.
16. Cayabyab MJ, Hovav AH, Hsu T, Krivulka GR, Lifton MA, et al. (2006) Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol 80: 1645-1652.
17. Hopkins R, Bridgeman A, Bourne C, Mbewe-Mwula A, Sadoff JC, et al. (2011) Optimizing HIV-1-specific CD8(+) T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol 41: 3542-3552.
18. Hopkins R, Bridgeman A, Joseph J, Gilbert SC, McShane H, et al. (2011) Dual neonate vaccine platform against HIV-1 and M. tuberculosis. PLoS One 6: e20067.
19. Im EJ, Saubi N, Virgili G, Sander C, Teoh D, et al. (2007) Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol 81: 9408-9418.
20. Rosario M, Fulkerson J, Soneji S, Parker J, Im EJ, et al. (2010) Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques. J Virol 84: 7815-7821.
21. Saubi N, Im EJ, Fernandez-Lloris R, Gil O, Cardona PJ, et al. (2011) Newborn mice vaccination with BCG.HIVA(2)(2)(2)+MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes. Clin Dev Immunol 2011: 516219.
22. Someya K, Ami Y, Nakasone T, Izumi Y, Matsuo K, et al. (2006) Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol. J Immunol 176: 1784-1795.
23. Yu JS, Peacock JW, Jacobs WR, Frothingham R, Letvin NL, et al. (2007) Recombinant Mycobacterium bovis Bacillus Calmette-Gue'rin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. Clinical and Vaccine Immunology 14: 886-893.
24. Rosario M, Hopkins R, Fulkerson J, Borthwick N, Quigley MF, et al. (2010) Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J Virol 84: 5898-5908.
25. Yu JS, Peacock JW, Jacobs WR, Frothingham R, Letvin NL, et al. (2007) Recombinant Mycobacterium bovis Bacillus Calmette-Gue'rin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. Clinical and Vaccine Immunology 14: 886-893.
26. Velaparthi S, Brunsteiner M, Uddin R, Wan B, Franzblau SG, et al. (2008) 5-tert-butyl-N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxam ide derivatives as novel potent inhibitors of Mycobacterium tuberculosis pantothenate synthetase: initiating a quest for new antitubercular drugs. J Med Chem 51: 1999-2002.
27. Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, et al. (2006) Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24: 6309-6320.
28. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA, (2008) A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect Immun 76: 5200-5214.
29. Hesseling AC, Schaaf HS, Hanekom WA, Beyers N, Cotton MF, et al. (2003) Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 37: 1226-1233.
30. Hesseling AC, Cotton MF, Marais BJ, Gie RP, Schaaf HS, et al. (2007) BCG and HIV reconsidered: moving the research agenda forward. Vaccine 25: 6565-6568.
31. Hinchey J, Jeon BY, Alley H, Chen B, Goldberg M, et al. (2011) Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis. PLoS One 6: e15857.
32. Hondalus MK, Bardarov S, Russell R, Chan J, Jacobs WR Jr, et al. (2000) Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect Immun 68: 2888-2898.
33. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, et al. (2002) A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8: 1171-1174.
34. Sampson SL, Dascher CC, Sambandamurthy VK, Russell RG, Jacobs WR, et al. (2004) Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infection and Immunity 72: 3031-3037.
35. Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, et al. (2009) Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27: 4412-4423.
36. Ranganathan UDK, Larsen MH, Kim J, Porcelli SA, Jacobs WR, et al. (2009) Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8(+) T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice. Vaccine 28: 152-161.
37. Al Zarouni M, Dale JW, (2002) Expression of foreign genes in Mycobacterium bovis BCG strains using different promoters reveals instability of the hsp60 promoter for expression of foreign genes in Mycobacterium bovis BCG strains. Tuberculosis 82: 283-291.
38. Haeseleer F, (1994) Structural instability of recombinant plasmids in mycobacteria. Res Microbiol 145: 683-687.
39. Kumar D, Srivastava BS, Srivastava R, (1998) Genetic rearrangements leading to disruption of heterologous gene expression in mycobacteria: an observation with Escherichia coli beta-galactosidase in Mycobacterium smegmatis and its implication in vaccine development. Vaccine 16: 1212-1215.
40. Masemola AM, Mashishi TN, Khoury G, Bredell H, Paximadis M, et al. (2004) Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. J Immunol 173: 4607-4617.
41. Chapman R, Chege G, Shephard E, Stutz H, Williamson AL, (2010) Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res 8: 282-298.
42. Cirillo JD, Stover CK, Bloom BR, Jacobs WR Jr, Barletta RG, (1995) Bacterial vaccine vectors and bacillus Calmette-Guerin. Clin Infect Dis 20: 1001-1009.
43. Joseph J, Saubi N, Pezzat E, Gatell JM, (2006) Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guerin: failures and challenges. Expert Rev Vaccines 5: 827-838.
44. Binder D, Kundig TM, (1991) Antiviral protection by CD8+ versus CD4+ T cells. CD8+ T cells correlating with cytotoxic activity in vitro are more efficient in antivaccinia virus protection than CD4-dependent IL. J Immunol 146: 4301-4307.
45. Dudani R, Chapdelaine Y, Faassen HH, Smith DK, Shen H, et al. (2002) Multiple mechanisms compensate to enhance tumor-protective CD8(+) T cell response in the long-term despite poor CD8(+) T cell priming initially: comparison between an acute versus a chronic intracellular bacterium expressing a model antigen. J Immunol 168: 5737-5745.
46. van Faassen H, Dudani R, Krishnan L, Sad S, (2004) Prolonged antigen presentation, APC-, and CD8+ T cell turnover during mycobacterial infection: comparison with Listeria monocytogenes. J Immunol 172: 3491-3500.
47. van Faassen H, Saldanha M, Gilbertson D, Dudani R, Krishnan L, et al. (2005) Reducing the stimulation of CD8+ T cells during infection with intracellular bacteria promotes differentiation primarily into a central (CD62LhighCD44high) subset. J Immunol 174: 5341-5350.
48. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by CD8(+) T cells is reflected by their avidity, polyfunctionality, and clonal turnover. Journal of Experimental Medicine 204: 2473-2485.
49. Douek DC, Roederer M, Koup RA, (2009) Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60: 471-484.
50. Richmond M, McKinnon LR, Kiazyk SA, Wachihi C, Kimani M, et al. (2011) Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function. J Virol 85: 1275-1286.
51. Yu JS, Peacock JW, Jacobs WR, Frothingham R, Letvin NL, et al. (2007) Recombinant Mycobacterium bovis Bacillus Calmette-Gue'rin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. Clinical and Vaccine Immunology 14: 886-893.
52. Shedlock DJ, Shen H, (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339.
53. Sun JC, Bevan MJ, (2003) Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339-342.
54. Kaushal D, Schroeder BG, Tyagi S, Yoshimatsu T, Scott C, et al. (2002) Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci U S A 99: 8330-8335.
55. Steyn AJ, Collins DM, Hondalus MK, Jacobs WR Jr, Kawakami RP, et al. (2002) Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. Proc Natl Acad Sci U S A 99: 3147-3152.
56. Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, et al. (2003) Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses 19: 133-144.
57. Parish T, Stoker NG, (1998) Electroporation of mycobacteria. In: Parish T, Stoker NG, editors. Mycobacterium tuberculosis Protocols pp. 129-144 Humana Press Inc, Totowa, New Jersey.
58. Wyatt LS, Shors ST, Murphy BR, Moss B, (1996) Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14: 1451-1458.
59. Mata M, Travers PJ, Liu Q, Frankel FR, Paterson Y, (1998) The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J Immunol 161: 2985-2993.
60. Mata M, Paterson Y, (1999) Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. J Immunol 163: 1449-1456.
61. van Harmelen JH, Shephard E, Thomas R, Hanke T, Williamson AL, et al. (2003) Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine 21: 4380-4389.